Percutaneous Sclerotherapy for Giant Symptomatic Liver Hemangiomas: A Pilot Study.
J Vasc Interv Radiol
; 29(2): 233-236, 2018 02.
Article
in En
| MEDLINE
| ID: mdl-29414196
ABSTRACT
This single-center prospective trial evaluated the safety and efficacy of percutaneous sclerotherapy for liver hemangiomas in 5 patients (1 man, 4 women; mean age 41.2 y) between 2016 and 2017. All patients were symptomatic (4 abdominal pain; 1 early satiety) and refused surgery. A single session of sclerotherapy with 20 cc mixture of 45 IU. Bleomycin in 10 cc distilled water and 10 cc Lipiodol (Ultra Fluide, Guerbet, France) was performed in all patients, achieving a 45.6%-71.1% lesion volume reduction and a 12.9%-41% reduction in the largest diameter of the lesion. Symptoms subsided in all patients during the 5-month follow-up period. Adverse events included a self-limited intraperitoneal hemorrhage in 1 patient.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sclerotherapy
/
Hemangioma
/
Liver Neoplasms
Type of study:
Diagnostic_studies
/
Observational_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Vasc Interv Radiol
Journal subject:
ANGIOLOGIA
/
RADIOLOGIA
Year:
2018
Document type:
Article
Affiliation country:
Iran